KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Income from Non-Controlling Interests (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Income from Non-Controlling Interests for 7 consecutive years, with $141.7 million as the latest value for Q4 2025.

  • Quarterly Income from Non-Controlling Interests rose 12.34% to $141.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $553.2 million through Dec 2025, up 17.26% year-over-year, with the annual reading at $553.2 million for FY2025, 17.26% up from the prior year.
  • Income from Non-Controlling Interests hit $141.7 million in Q4 2025 for Royalty Pharma, down from $156.0 million in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of $366.0 million in Q2 2021 to a low of -$153.9 million in Q4 2022.
  • Historically, Income from Non-Controlling Interests has averaged $120.0 million across 5 years, with a median of $121.8 million in 2021.
  • Biggest five-year swings in Income from Non-Controlling Interests: tumbled 436.37% in 2022 and later surged 2255.39% in 2025.
  • Year by year, Income from Non-Controlling Interests stood at $45.8 million in 2021, then crashed by 436.37% to -$153.9 million in 2022, then soared by 245.02% to $223.2 million in 2023, then crashed by 43.5% to $126.1 million in 2024, then rose by 12.34% to $141.7 million in 2025.
  • Business Quant data shows Income from Non-Controlling Interests for RPRX at $141.7 million in Q4 2025, $156.0 million in Q3 2025, and $60.5 million in Q2 2025.